Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets
(Source: JNCI)
Source: JNCI - February 9, 2016 Category: Cancer & Oncology Authors: Brower, V. Tags: News Source Type: research
E-Cigarettes May Lead to Youth Tobacco Use: Evidence Mounts
(Source: JNCI)
Source: JNCI - February 9, 2016 Category: Cancer & Oncology Authors: Fillon, M. Tags: News Source Type: research
Genomic Testing for Gemcitabine-Based Treatment of Pancreatic Cancer
(Source: JNCI)
Source: JNCI - February 8, 2016 Category: Cancer & Oncology Authors: Zhang, J., Hochwald, S. N. Tags: Solicited Editorial Source Type: research
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer
Conclusions:
WWOX rs11644322 represents a major predictive factor in gemcitabine-treated pancreatic cancer. Decreased WWOX expression may interfere with gemcitabine sensitivity, and allele-specific binding at rs11644332 might be a causative molecular mechanism behind the observed clinical associations. (Source: JNCI)
Source: JNCI - February 8, 2016 Category: Cancer & Oncology Authors: Schirmer, M. A., Lüske, C. M., Roppel, S., Schaudinn, A., Zimmer, C., Pflüger, R., Haubrock, M., Rapp, J., Güngör, C., Bockhorn, M., Hackert, T., Hank, T., Strobel, O., Werner, J., Izbicki, J. R., Johnsen, S. A., Gaedcke, J Tags: Article Source Type: research
Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7
Conclusions:
YB-1 appears to be a promising target to inhibit the development of castration resistance, even at the AR variant–expressing stage. Polymorphism in the YB-1 gene may be a promising predictive biomarker in hormonal therapy. (Source: JNCI)
Source: JNCI - February 8, 2016 Category: Cancer & Oncology Authors: Shiota, M., Fujimoto, N., Imada, K., Yokomizo, A., Itsumi, M., Takeuchi, A., Kuruma, H., Inokuchi, J., Tatsugami, K., Uchiumi, T., Oda, Y., Naito, S. Tags: Article Source Type: research
Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways
Conclusions:
Our findings suggest a role of IRF4 rs12203592 in pathway-specific risk for melanoma development. We hypothesize that IRF4 rs12203592 could underlie in part the bimodal age distribution reported for melanoma and linked to the divergent pathways. (Source: JNCI)
Source: JNCI - February 8, 2016 Category: Cancer & Oncology Authors: Gibbs, D. C., Orlow, I., Bramson, J. I., Kanetsky, P. A., Luo, L., Kricker, A., Armstrong, B. K., Anton-Culver, H., Gruber, S. B., Marrett, L. D., Gallagher, R. P., Zanetti, R., Rosso, S., Dwyer, T., Sharma, A., La Pilla, E., From, L., Busam, K. J., Cust, Tags: Article Source Type: research
Response
(Source: JNCI)
Source: JNCI - February 7, 2016 Category: Cancer & Oncology Authors: Figueroa, J. D., Prokunina-Olsson, L., Koutros, S., Garcia-Closas, M., Chanock, S., Silverman, D. T., Rothman, N. Tags: Response Source Type: research
RE: Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms
(Source: JNCI)
Source: JNCI - February 7, 2016 Category: Cancer & Oncology Authors: Selinski, S., Krech, E., Ovsiannikov, D., Blaszkewicz, M., Hengstler, J. G., Golka, K. Tags: Correspondence Source Type: research
Regorafenib Also Can Cause Osteonecrosis of the Jaw
(Source: JNCI)
Source: JNCI - February 7, 2016 Category: Cancer & Oncology Authors: Antonuzzo, L., Lunghi, A., Giommoni, E., Brugia, M., Di Costanzo, F. Tags: Correspondence Source Type: research
One Good DNA Damage Deserves Another: Oxaliplatin in MSI-High Colon Cancer
(Source: JNCI)
Source: JNCI - February 5, 2016 Category: Cancer & Oncology Authors: Hochster, H. S., Sargent, D. J. Tags: Solicited Editorial Source Type: research
One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer
(Source: JNCI)
Source: JNCI - February 5, 2016 Category: Cancer & Oncology Authors: Hochster, H. S., Sargent, D. J. Tags: Solicited Editorial Source Type: research
Antitumor Activity of BRAF Inhibitor and IFN{alpha} Combination in BRAF-Mutant Melanoma
Conclusions:
The described results provide a strong rationale for the clinical trials implemented in BRAFV600E melanoma patients with BRAF-I and IFNα combination. (Source: JNCI)
Source: JNCI - February 5, 2016 Category: Cancer & Oncology Authors: Sabbatino, F., Wang, Y., Scognamiglio, G., Favoino, E., Feldman, S. A., Villani, V., Flaherty, K. T., Nota, S., Giannarelli, D., Simeone, E., Anniciello, A. M., Palmieri, G., Pepe, S., Botti, G., Ascierto, P. A., Ferrone, C. R., Ferrone, S. Tags: Article Source Type: research
BRAF Inhibitors and IFN{alpha}: Plus, Minus, or Indeterminate?
(Source: JNCI)
Source: JNCI - February 5, 2016 Category: Cancer & Oncology Authors: Davar, D., Fuchs, S. Y., Kirkwood, J. M. Tags: Solicited Editorial Source Type: research
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Conclusions:
FATSI screening showed that a substantial number of patients’ tumors have FA functional deficiency, which led to germline alterations in several patients’ tumors. Veliparib alone or with MMC was safely administered to these patients and produced clinical benefit in some. However, a better understanding of resistance mechanisms in this setting is needed. (Source: JNCI)
Source: JNCI - February 4, 2016 Category: Cancer & Oncology Authors: Villalona-Calero, M. A., Duan, W., Zhao, W., Shilo, K., Schaaf, L. J., Thurmond, J., Westman, J. A., Marshall, J., Xiaobai, L., Ji, J., Rose, J., Lustberg, M., Bekaii-Saab, T., Chen, A., Timmers, C. Tags: Article Source Type: research
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives
The advent of newer immunotherapeutic and molecularly targeted agents has provided a number of effective options for cancer treatment but has also added much complexity in selecting the best initial treatment or treatment plan for each patient. Molecularly targeted agents offer selectivity and are the cornerstone for "precision medicine." While targeted agents are associated with high tumor response rates, patients inevitably develop resistance to these drugs. Immunotherapies exploit the endogenous immune system to eradicate cancer and can produce durable disease control that results in long-term, treatment-free survival i...
Source: JNCI - February 2, 2016 Category: Cancer & Oncology Authors: Atkins, M. B., Larkin, J. Tags: Review Source Type: research
